These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Towards the Development of a Targeted Albumin-Binding Radioligand for Theranostic Applications: Synthesis, Radiolabelling and Preliminary In Vivo Studies

submitted on 22.07.2020, 10:08 and posted on 22.07.2020, 12:59 by Cathryn H.S. Driver, Thomas Ebenhan, Jan Rijn Zeevaart, Roger Hunter, Iqbal Parker, Zoltan Szucs
GluCAB is a newly synthesised macrocyclic radioligand designed to bind in vivo to albumin (HSA) for the purpose of development as a dual-targeting oncological theranostic agent. Subsequent to its synthesis and 64Cu-radiolabelling, this radioligand has show a prolonged circulation time in healthy mice but with appropriate systemic clearance within 24 h. This radioligand meets the criteria to be further investigated for tumour targeting and uptake.


Email Address of Submitting Author


South African Nuclear Energy Corporation


South Africa

ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest to declare

Version Notes

Full Article revised to remove Journal watermark and header